About Step Pharma

Step PharmaInhibition of CTP Synthase 1  a targeted approach to block T and B cell proliferation in haematological cancers and auto-immune diseases

Step Pharma is developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). Our most advanced programme is STP938 which is being developed as a targeted therapy for T-cell malignancies.

Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation.

Step Pharma has developed a series of potent, selective, orally available small molecular weight inhibitors of CTPS1 with STP938 expected to enter clinical development in 2022. The role of CTPS1 in modulating lymphocytes has been genetically validated and we have shown in preclinical experiments the potential for CTPS1 inhibitors to reduce disease severity in models of autoimmune disease and inhibit T- and B-cell proliferation in models of cancer.

Step Pharma continues to work closely with our scientific founders Prof Alain Fischer and Prof Sylvain Latour benefiting from their extensive experience in immunology. In addition we have a strong management team and a committed investor group.

The Team

Chief Executive Officer
Chief Development Officer
Chief Financial Officer
Senior Director
Head of Pharmacology
VP, Head of Research
and Translational Medicine
Vice President
Head of Clinical Operations
Chief Medical Officer

The Board

Chairman of the Board, Independent Director
CEO of AM Pharma
Independent Director
CEO of Enyo Pharma
Managing Partner, Kurma Partners
CEO and Founder of Sygnature Discovery
Investment Director, Sunstone Lifes Science Ventures
Investment director, Bpifrance
Managing Partner, Hadean Ventures
Partner Pontifax
Independent Director

Scientific founders


Share this page